PharmaLytica 2021 Hyderabad review.

abc

abc

Phase III clinical trial of Molnupiravir initiated by MSN Laboratories

Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID treatment. MSN research and development team has developed both the API and formulation, is expecting to launch soon after its successful conclusion of clinical study followed by regulatory approval

26th May, 2021 Mumbai

MSN Laboratories Private Limited (MSN) is initiating phase III clinical trial of Molnupiravir capsules for the treatment of COVID-19 in India.

After the launch of Posaone (Posaconazole) tablet used in the treatment of black fungus, MSN on Wednesday announced that it received a clearance from the Drug Controller General of India (DGCI) last week to conduct a third phase of clinical trial on mild to moderate COVID-19 patients.

Set up in Hyderabad, MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate COVID-19, the company said in a statement.

Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID treatment. MSN research and development team has developed both the API and formulation, is expecting to launch soon after its successful conclusion of clinical study followed by regulatory approval, it added.

As part of the COVID-19 treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, OSELOW (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly.

As of now, India is administering Remdesivir developed by the biopharmaceutical company Gilead Sciences in case of severity of COVID-19 patients. Also, Fabiflu Tablet, an antiviral medicine, is also being used for the treatment of mild to moderate coronavirus disease in adults.

The daily COVID-19 positivity rate in India has reduced and now stands at 9.42 percent, while the recoveries continue to outnumber the new cases for the 13th consecutive day, said the Ministry of Health and Family Welfare on Wednesday.

AstraZeneca and Russia's Sputnik V are the only two vaccine manufacturers which have participated in a pre-bid meeting held by Telangana government for procuring 10 million doses of Covid-19 vaccine, though the conference witnessed participation of a few trade representatives, sources said on Thursday. The pre-bid meeting was held on May 26.

abc

abc

×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More